Show simple item record

dc.contributor.authorPerez Chacon, Gladymar
dc.contributor.authorEstcourt, Marie J
dc.contributor.authorTotterdell, James
dc.contributor.authorCampbell, Dianne E
dc.contributor.authorPerrett, Kirsten P
dc.contributor.authorMarsh, Julie A
dc.contributor.authorRichmond, Peter C
dc.contributor.authorWood, Nicholas
dc.contributor.authorGold, Michael S
dc.contributor.authorHolt, Patrick G
dc.contributor.authorWaddington, Claire S
dc.contributor.authorSnelling, Thomas L
dc.date.accessioned2022-05-16T08:00:26Z
dc.date.available2022-05-16T08:00:26Z
dc.date.issued2020-12-17
dc.date.submitted2020-07-16
dc.identifier.issn2044-6055
dc.identifier.otherbmjopen-2020-042838
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/337184
dc.description.abstractINTRODUCTION: Combination vaccines containing whole-cell pertussis antigens were phased out from the Australian national immunisation programme between 1997 and 1999 and replaced by the less reactogenic acellular pertussis (aP) antigens. In a large case-control study of Australian children born during the transition period, those with allergist diagnosed IgE-mediated food allergy were less likely to have received whole-cell vaccine in early infancy than matched population controls (OR: 0.77 (95% CI, 0.62 to 0.95)). We hypothesise that a single dose of whole-cell vaccine in early infancy is protective against IgE-mediated food allergy. METHODS AND ANALYSIS: This adaptive double-blind randomised controlled trial is investigating whether a mixed whole-cell/aP vaccine schedule prevents allergic disease in the first year of life. The primary outcome is IgE-mediated food allergy by 12 months of age. Secondary outcomes include new onset of atopic dermatitis by 6 or 12 months of age; sensitisation to at least one allergen by 12 months of age; seroconversion in anti-pertussis toxin IgG titres after vaccination with aP booster at 18 months of age; and solicited systemic and local adverse events following immunisation with pertussis-containing vaccines. Analyses will be performed using a Bayesian group sequential design. ETHICS AND DISSEMINATION: This study has been approved by the Child and Adolescent Health Service Human Research Ethics Committee, Perth, Western Australia (RGS 00019). The investigators will ensure that this trial is conducted in accordance with the principles of the Declaration of Helsinki and with the International Conference on Harmonisation Guidelines for Good Clinical Practice. Individual consent will be requested. Parents will be reimbursed reasonable travel and parking costs to attend the study visits. The dissemination of these research findings will follow the National Health and Medical Research Council of Australia Open Access Policy. TRIAL REGISTRATION NUMBER: ACTRN12617000065392p.
dc.languageen
dc.publisherBMJ
dc.subjectImmunology (including allergy)
dc.subject1506
dc.subject1705
dc.subjectpaediatric infectious disease and immunisation
dc.subjectallergy
dc.subjectimmunology
dc.titleOPTIMUM study protocol: an adaptive randomised controlled trial of a mixed whole-cell/acellular pertussis vaccine schedule.
dc.typeArticle
dc.date.updated2022-05-16T08:00:26Z
prism.issueIdentifier12
prism.publicationNameBMJ Open
prism.volume10
dc.identifier.doi10.17863/CAM.84603
dcterms.dateAccepted2020-11-12
rioxxterms.versionofrecord10.1136/bmjopen-2020-042838
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by-nc/4.0/
rioxxterms.licenseref.startdate2020-12-17
dc.contributor.orcidPerez Chacon, Gladymar [0000-0001-6629-1603]
dc.identifier.eissn2044-6055
cam.issuedOnline2020-12-17
rioxxterms.freetoread.startdate2020-12-17
rioxxterms.freetoread.startdate2020-12-17


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record